FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W103139616> ?p ?o ?g. }

• W103139616 endingPage "774" @default.
• W103139616 startingPage "768" @default.
• W103139616 abstract "The aim of this study was to evaluate the long-term safety and durability of efficacy of tadalafil for pulmonary arterial hypertension. Tadalafil is an oral phosphodiesterase-5 inhibitor approved for PAH treatment. In the multicenter, placebo-controlled, randomized, 16-week PHIRST (Pulmonary Arterial Hypertension and Response to Tadalafil) study, tadalafil 40 mg improved exercise capacity and delayed clinical worsening. Eligible patients from PHIRST received once-daily tadalafil 20 mg (T20 mg) or 40 mg (T40 mg) (n = 357) in the double-blind, 52-week, uncontrolled extension study (PHIRST-2); 293 patients completed PHIRST-2. Durability of efficacy was explored using the 6-min walk distance (6MWD) test. Clinical worsening and changes in World Health Organization functional class were evaluated. The safety profile of tadalafil in PHIRST-2 was similar to that in PHIRST, with typical phosphodiesterase-5 inhibitor adverse events. The 6MWDs achieved in PHIRST for the subset of patients receiving T20 mg and T40 mg in both PHIRST and PHIRST-2 (406 ± 67 m [n = 52] and 413 ± 81 m [n = 59] at PHIRST-2 enrollment, respectively) were maintained at PHIRST-2 completion (415 ± 80 m [n = 51] and 410 ± 78 m [n = 59], respectively). Numerically fewer patients who were on T40 mg in PHIRST and PHIRST-2 experienced World Health Organization functional class deterioration (6% [n = 5]) compared with those randomized to T20 mg (9% [n = 7]) across both studies. Post hoc analyses showed that background bosentan use and higher 6MWD at PHIRST baseline were associated with fewer clinical worsening events. Long-term treatment with tadalafil was well tolerated in patients with pulmonary arterial hypertension. In patients receiving either T20 mg or T40 mg, the improvements in 6MWD demonstrated in the 16-week PHIRST study appeared sustained for up to 52 additional weeks of treatment in PHIRST-2. (Pulmonary Arterial Hypertension and Response to Tadalafil Study; NCT00549302)" @default.
• W103139616 created "2016-06-24" @default.
• W103139616 creator A5001533816 @default.
• W103139616 creator A5031477165 @default.
• W103139616 creator A5051731762 @default.
• W103139616 creator A5053421758 @default.
• W103139616 creator A5054713480 @default.
• W103139616 creator A5065469571 @default.
• W103139616 creator A5070323256 @default.
• W103139616 creator A5083839456 @default.
• W103139616 creator A5087381976 @default.
• W103139616 date "2012-08-01" @default.
• W103139616 modified "2023-10-15" @default.
• W103139616 title "Tadalafil for the Treatment of Pulmonary Arterial Hypertension" @default.
• W103139616 cites W1994219663 @default.
• W103139616 cites W2090477853 @default.
• W103139616 cites W2090878184 @default.
• W103139616 cites W2110637500 @default.
• W103139616 cites W2114234606 @default.
• W103139616 cites W2127994875 @default.
• W103139616 cites W2134688317 @default.
• W103139616 cites W2148038451 @default.
• W103139616 cites W2150889420 @default.
• W103139616 cites W2150989458 @default.
• W103139616 cites W2155231007 @default.
• W103139616 cites W3140907331 @default.
• W103139616 doi "https://doi.org/10.1016/j.jacc.2012.05.004" @default.
• W103139616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22818063" @default.
• W103139616 hasPublicationYear "2012" @default.
• W103139616 type Work @default.
• W103139616 sameAs 103139616 @default.
• W103139616 citedByCount "119" @default.
• W103139616 countsByYear W1031396162012 @default.
• W103139616 countsByYear W1031396162013 @default.
• W103139616 countsByYear W1031396162014 @default.
• W103139616 countsByYear W1031396162015 @default.
• W103139616 countsByYear W1031396162016 @default.
• W103139616 countsByYear W1031396162017 @default.
• W103139616 countsByYear W1031396162018 @default.
• W103139616 countsByYear W1031396162019 @default.
• W103139616 countsByYear W1031396162020 @default.
• W103139616 countsByYear W1031396162021 @default.
• W103139616 countsByYear W1031396162022 @default.
• W103139616 countsByYear W1031396162023 @default.
• W103139616 crossrefType "journal-article" @default.
• W103139616 hasAuthorship W103139616A5001533816 @default.
• W103139616 hasAuthorship W103139616A5031477165 @default.
• W103139616 hasAuthorship W103139616A5051731762 @default.
• W103139616 hasAuthorship W103139616A5053421758 @default.
• W103139616 hasAuthorship W103139616A5054713480 @default.
• W103139616 hasAuthorship W103139616A5065469571 @default.
• W103139616 hasAuthorship W103139616A5070323256 @default.
• W103139616 hasAuthorship W103139616A5083839456 @default.
• W103139616 hasAuthorship W103139616A5087381976 @default.
• W103139616 hasBestOaLocation W1031396161 @default.
• W103139616 hasConcept C126322002 @default.
• W103139616 hasConcept C142724271 @default.
• W103139616 hasConcept C144980905 @default.
• W103139616 hasConcept C168563851 @default.
• W103139616 hasConcept C170493617 @default.
• W103139616 hasConcept C197934379 @default.
• W103139616 hasConcept C204787440 @default.
• W103139616 hasConcept C27081682 @default.
• W103139616 hasConcept C2779929075 @default.
• W103139616 hasConcept C2780816001 @default.
• W103139616 hasConcept C2780930700 @default.
• W103139616 hasConcept C2781109936 @default.
• W103139616 hasConcept C42219234 @default.
• W103139616 hasConcept C67761136 @default.
• W103139616 hasConcept C71924100 @default.
• W103139616 hasConcept C74534348 @default.
• W103139616 hasConceptScore W103139616C126322002 @default.
• W103139616 hasConceptScore W103139616C142724271 @default.
• W103139616 hasConceptScore W103139616C144980905 @default.
• W103139616 hasConceptScore W103139616C168563851 @default.
• W103139616 hasConceptScore W103139616C170493617 @default.
• W103139616 hasConceptScore W103139616C197934379 @default.
• W103139616 hasConceptScore W103139616C204787440 @default.
• W103139616 hasConceptScore W103139616C27081682 @default.
• W103139616 hasConceptScore W103139616C2779929075 @default.
• W103139616 hasConceptScore W103139616C2780816001 @default.
• W103139616 hasConceptScore W103139616C2780930700 @default.
• W103139616 hasConceptScore W103139616C2781109936 @default.
• W103139616 hasConceptScore W103139616C42219234 @default.
• W103139616 hasConceptScore W103139616C67761136 @default.
• W103139616 hasConceptScore W103139616C71924100 @default.
• W103139616 hasConceptScore W103139616C74534348 @default.
• W103139616 hasFunder F4320307758 @default.
• W103139616 hasIssue "8" @default.
• W103139616 hasLocation W1031396161 @default.
• W103139616 hasLocation W1031396162 @default.
• W103139616 hasOpenAccess W103139616 @default.
• W103139616 hasPrimaryLocation W1031396161 @default.
• W103139616 hasRelatedWork W1570577237 @default.
• W103139616 hasRelatedWork W1898711703 @default.
• W103139616 hasRelatedWork W1970200839 @default.
• W103139616 hasRelatedWork W1999638102 @default.
• W103139616 hasRelatedWork W2024530569 @default.

• next